

# How Does the Brain Fill-in the Visual World?



## Geraint Rees

is a Professor of Cognitive Neurology and Wellcome Senior Clinical Fellow at the Institute of Cognitive Neuroscience and the Wellcome Trust Centre for Neuroimaging, University College London. His research focuses on the neural basis of consciousness in health and disease.



## Rimona Weil

is an MRC Clinical Research Training Fellow in Cognitive Neurology currently undertaking a PhD at the Wellcome Trust Centre for Neuroimaging at University College London. Her research focuses on the integration of bottom-up and top-down signals in human perception in health and disease.

### Correspondence to:

Dr Rimona Weil,  
Wellcome Trust Centre for  
Neuroimaging,  
12 Queen Square,  
London WC1N 3BG, UK.  
Tel: +44 20 7833 7472  
Fax: +44 20 7813 1420  
Email: rweil@fil.ion.ucl.ac.uk

Our awareness of the visual environment comes to us from the pattern of light on the retina. But this pattern is an incomplete record of the visual scene, because many pieces of the scene fall on the blind spot or are obscured by retinal vessels. This loss of information can be worsened by disease-induced retinal damage, or when cortical injury following stroke damages areas of visual cortex corresponding to parts of the visual field. Yet healthy people and most patients are largely unaware of this missing or incomplete information. Instead, we see the visual scene as though it were complete because the brain ‘fills-in’ the missing information. The neural mechanisms involved in such perceptual ‘filling-in’ can tell us a great deal about normal visual processes, and are also likely to be involved when parts of the visual system are damaged and more extensive filling-in takes place.

### Filling-in at the blind spot

Although the blind spot is devoid of photoreceptors and carries no visual information from the corresponding region in visual space, when we view the world through one eye, we don’t see a blank patch: the visual system fills-in the missing information from the surrounding colour or pattern (Figure 1). Behavioural studies in healthy people suggest that filling-in at the blind spot is a rapid, preattentive process that occurs early in the visual system. For example, if several rings are viewed, but with one positioned in the visual field so its retinal projection lies just around the blind spot, then this particular ring will ‘pop out’ of the group as it is perceived not as a ring, but as a filled-in disc among the other rings that do not lie over the blind spot.<sup>1</sup> Even an extremely narrow border (0.05 deg) surrounding the blind spot, will generate the appearance of uniform colour filling-in the blind spot,<sup>2</sup> consistent with the theory that such filling-in depends on local processes generated at the edge of the blind spot representation in primary visual cortex. Single cell recordings

from anaesthetised monkeys show that when filling-in takes place at the blind spot, neural responses are generated at the retinotopic representation of the blind spot in primary visual cortex.<sup>3,4</sup> However, the precise mechanism by which perceptual filling-in across the blind spot occurs is still unknown. The two main theories are that it involves lateral propagation of signals from the edge of the blind spot, or is due to remapping of receptive fields of surrounding neurons into the blind spot region.<sup>5</sup>

### Filling-in after prolonged fixation

Filling-in also takes place in normal vision during prolonged fixation. For example, a figure viewed in the periphery on a bland and featureless background will seem to disappear after a few seconds of prolonged fixation, to be replaced by the background (see Figure 2a). This type of filling-in is known as Troxler fading.<sup>6</sup> A similar but more striking effect is seen if the featureless background is replaced by a dynamic texture, similar to the static on a television set. This dynamic background promotes rapid filling-in of even quite salient figures placed on top of the background, and the resultant effect is described as an ‘artificial scotoma’ because the figure becomes invisible and ‘filled in’ by the textured background<sup>7</sup> (see Figure 2b). These ‘artificial scotomas’ may be associated with similar neural processes that lead to the filling-in which takes place when targets are stabilised on the retina, as eye movements disrupt the artificial scotoma.<sup>8</sup> Behavioural studies suggest that the filling-in associated with an artificial scotoma takes place in early retinotopic cortex as it is influenced by low-level sensory factors such as eccentricity and boundary length of the figure that ‘fills-in’.<sup>9,10</sup> This is consistent with single cell studies in monkeys<sup>11</sup> and neuroimaging reports in humans.<sup>12,13</sup> However, recent work suggests that higher cognitive factors may also play a role, as directing spatial attention to the peripheral figure makes it



Figure 1: Examples of perceptual filling-in at the blind spot. Hold the page approximately 15 cm from your face, close your right eye and fixate the cross with your left eye while attending to the horizontal bars. Move the page gently closer and/or further away from you until the green disc falls into the blind spot. When the green disc falls across the blind spot, it will disappear and the space it occupies will be perceptually filled-in by the horizontal bars. Now close your left eye and fixate the cross with your right eye while attending to the pink and yellow target. Again, move the page closer and further away until the target falls into the blind spot. When the yellow disc falls across the blind spot, the appearance will be of a large pink circle, with the yellow disc disappearing and becoming filled-in by the surrounding pink. Similar to example shown in Komatsu, H. *Nature Reviews Neuroscience*, 2006;7:220-31.

## ABBREVIATED PRESCRIBING INFORMATION

(Please consult the Summary of Product Characteristics (SPC) before prescribing.)

KEPPRA® film-coated tablets 250 mg, 500 mg, 750 mg, 1000 mg

KEPPRA® 100 mg/ml oral solution

KEPPRA® 100 mg/ml concentrate for solution for infusion

**Active Ingredient:** Tablets: levetiracetam 250, 500, 750 and 1000 mg. Oral

**Solution:** levetiracetam 100 mg per ml. **Infusion:** levetiracetam 100 mg per ml.

**Uses:** Monotherapy for partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy. Adjunctive therapy for partial onset seizures with or without secondary generalisation in adults and children from 4 years of age, for myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy and for primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

**Infusion:** an alternative for patients when oral administration is temporarily not feasible.

**Dosage and Administration:** Oral solution should be diluted prior to use. Infusion: Keppra concentrate must be diluted in at least 100 ml of a compatible diluent and administered intravenously as a 15-minute infusion.

**Monotherapy (adults and adolescents from 16 years):** Recommended starting dose of 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500 mg twice daily.

**Adjunctive therapy: Adults and adolescents older than 12 years or weighing 50 kg or more:** 500 mg twice daily can be increased up to 1500 mg twice daily. Dose changes can be made in 500 mg twice daily increases or decreases every two to four weeks.

**Elderly:** Adjustment of the dose is recommended in patients with compromised renal function.

**Children aged 4 to 11 years and adolescents (12 to 17 years) of less than 50 kg:** 10 mg/kg twice daily, increased up to 30 mg/kg twice daily. Do not exceed increases or decreases of 10 mg/kg twice daily every two weeks. The lowest effective dose should be used. (For full dosage recommendations see SPC.)

**Patients with renal impairment:** Adjust dose according to creatinine clearance as advised in SPC.

**Patients with hepatic impairment:** No dose adjustment with mild to moderate hepatic impairment.

With severe hepatic impairment (creatinine clearance <70ml/min) a 50% reduction of the daily maintenance dose is recommended, as the creatinine clearance may underestimate the renal insufficiency.

**Contraindications, Warnings etc.:** **Contraindications:** Hypersensitivity to levetiracetam, other pyrrolidone derivatives or excipients.

**Precautions:** If discontinuing treatment reduce dose gradually as advised in SPC. Due to its excipients, the oral solution may cause allergic reactions (possibly delayed).

**Infusion:** Keppra concentrate contains 7.196 mg of sodium per vial. To be taken into consideration by patients on a controlled sodium diet. Monitor patients for signs of suicidal ideation and behaviours. Advise patients and carers to seek medical advice should such signs emerge.

**Interactions:** Keppra did not affect serum concentrations of phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin or primidone. Drugs excreted by active tubular secretion could reduce the renal clearance of the metabolite. Levetiracetam 1000 mg daily did not affect the pharmacokinetics of oral contraceptives (ethinyl-estradiol and levonorgestrel). Levetiracetam 2000 mg daily did not affect the pharmacokinetics of digoxin and warfarin and prothrombin times were not modified.

**Pregnancy and lactation:** Should not be used during pregnancy unless clearly necessary. Breast-feeding not recommended.

**Driving, etc.:** Caution recommended when performing skilled tasks, e.g. driving vehicles or operating machinery.

**Adverse Effects:** Incidence of undesirable effects considered to be at least possibly related in controlled clinical studies. **Very common (≥10%):** asthenia/fatigue, somnolence. **Common (between 1%–10%):** GI disturbances, anorexia, weight increase, accidental injury, headache, dizziness, hyperkinesia, tremor, ataxia, convulsion, amnesia, balance disorder, disturbances in attention, memory impairment, emotional lability/mood swings, hostility, depression, insomnia, nervousness/irritability, agitation, personality disorders, thinking abnormal, vertigo, rash, eczema, pruritus, diplopia, vision blurred, myalgia, infection, nasopharyngitis, cough increased, thrombocytopenia. Consult SPC in relation to other side effects.

**Pharmaceutical Precautions:** Tablets: None. Oral solution: Store in original container. After first opening use within 2 months. Infusion: Use immediately after dilution.

**Legal Category:** POM.

**Marketing Authorisation Numbers:** 250 mg x 60 tabs: EU/1/00/146/004. 500 mg x 60 tabs: EU/1/00/146/010. 750 mg x 60 tabs: EU/1/00/146/017. 1000 mg x 60 tabs: EU/1/00/146/024. Solution x 300 ml: EU/1/146/027, Infusion (500 mg/5 ml) x 10 vials: EU/1/00/146/030. **NHS Cost:** 250 mg x 60 tabs: £29.70. 500 mg x 60 tabs: £52.30. 750 mg x 60 tabs: £89.10. 1000 mg x 60 tabs: £101.10. Solution x 300 ml: £71.00, Infusion (500 mg/ 5ml) x 10 vials: £135.00.

**Name and Address of PL Holder:** UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium. **Further information is available from:** UCB Pharma Ltd., 208 Bath Road, Slough, Berkshire, SL1 3WE. Tel: 01753 534655. Fax: 01753 536632. Email: medicalinformationuk@ucb.com **Date of Revision:** January 2009




Figure 2: Filling-in after prolonged fixation. (a) Example of Troxler fading.<sup>7</sup> Hold the page 20cm away from your face, fixate the cross with both eyes open, after a few seconds, the blue pattern will fade and disappear.

(b) Example of an artificial scotoma. A square figure is placed in the near periphery on the background of dynamic twinkling noise. Participants fixate centrally and the square figure gradually fades and disappears.




Figure 3: Occluded objects (a,b) Visual search with for amodally completed target.

Identifying the notched circle is harder in (A) as it is amodally completed and perceived as a circle among the other circles. In (B), the notched circle 'pops out'. Search display similar to those used in<sup>8</sup> (c,d) Depth cues to identify occluded objects. The left-hand image (c) is difficult to interpret. (d) Adding a blue snakelike occluder helps to define the occluded figures as uppercase Bs. Similar to example shown in Nakayama et al., 1989.<sup>9</sup>

more likely to 'fill in' and disappear.<sup>14</sup> Thus, although filling-in may be generated by low-level, early retinotopic neural processes, it is also modulated by higher cognitive factors.

### Filling-in behind occluders

The world is very cluttered and most objects do not present themselves in isolation but are seen at least partially occluded by other objects. Yet we do not have the impression of being surrounded by fragmented objects. The brain 'fills-in' the missing information and our impression is the familiar one of viewing complete objects. This type of filling-in of objects behind occluders is also known as amodal completion and seems to occur at slightly later stages of visual processing than the filling-in of artificial scotomas and the blind spot. The effects of amodal completion can be seen when subjects are asked to search for a notched circle

Adverse events should be reported. Reporting forms and information can be found at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk)  
Adverse events should also be reported to UCB Pharma Ltd.

© 2009 UCB Pharma Ltd.  
© Keppra is a registered trade mark of UCB Pharma Ltd.  
Date of preparation: February 2009.  
08KP0188



in an array of circles and squares. If the notched circle abuts the edge of one of the squares so that it seems to be occluded by it, the notched circle takes longer to find (see Figure 3a)<sup>15</sup> as it is perceived as a complete circle in a sea of complete circles. Occluded objects are also easier to recognise than those with the equivalent portions deleted (see Figure 3b)<sup>16,17</sup> suggesting that inferred depth is used to inform the visual system of object boundaries, as objects are far more likely to be partly occluded than have bits missing. This would suggest some involvement of object related areas in identifying occluded items. Indeed, a recent neuroimaging study showed increased activity during presentation of occluded objects in the lateral occipital complex (LOC), a region known to be involved in object processing; and in the posterior intraparietal region.<sup>18,19</sup> The process of filling-in behind occluders is likely to involve a large number of information processing steps such as distinguishing between the boundaries of the occluded and the occluding object, assigning each of the resulting partial views a surface and then filling-in the missing information of each part<sup>17</sup> using clues from depth disparity and colinear edges.

## Understanding the processes involved in filling-in in the healthy brain can provide insights into filling-in following visual loss

### Filling-in as a response to disorders of vision

Patients with retinal scotomas due to macular degeneration and toxoplasma also experience perceptual filling-in.<sup>20,22</sup> This can be problematic, especially in age-related macular degeneration, as early detection of the macular disease is essential to preserve foveal function with newer treatments<sup>29</sup> and when patients fill-in across their scotomas they are unaware of their visual field deficits.

The mechanisms of filling-in across retinal scotomas are still debated. In monkeys, cells within primary visual cortex representing the lesion expand their receptive fields within minutes after inducing a retinal lesion<sup>24</sup> and several months after the lesion, the receptive fields have expanded and shifted to outside the lesion. Similar reports of receptive field reorganisation in V1 (primary visual cortex) have been shown in retinal lesions in cats<sup>25,26</sup> and following cortical lesions in kittens.<sup>27</sup> In humans, reports are less consistent. Visual cortex (including V1) deprived of retinal input due to macular degeneration shows increased activation with functional MRI to stimuli outside the corresponding region in visual space.<sup>28,30</sup> Reorganisation also occurs following loss of visual input due to optic radiation damage following stroke.<sup>29</sup> However, other studies have failed to find consistent evidence for cortical reorganisation in macular degeneration<sup>31</sup> and a recent study suggests that large scale cortical reorganisation may only occur with complete absence of functional foveal vision.<sup>30</sup> The processes underlying this cortical reorganisation remain unknown. One possibility is that it arises from disinhibition of pre-existing long-range horizontal connections in V1,<sup>32</sup> but this would require connections longer than those known to occur in primate V1.<sup>33</sup> Alternatively, new horizontal connections might be formed.<sup>34</sup> A third possibility is that reorganisation occurs due to new or unmasked feedback projections from higher visual areas with larger receptive fields (see also reference 35 for an example).<sup>35</sup>

### Conclusion

Perceptual filling-in, in many different forms, plays a critical role in completing missing information in normal human vision and is also a consequence of visual loss. The mechanisms are likely to differ between the various types of filling-in but may be important in designing treatments to encourage cortical reorganisation following damage to visual structures. ♦

### REFERENCES

- Ramachandran VS. *Filling in the blind spot*. *Nature* 1992;356:115.
- Spillmann L, Otte T, Hamburger K, Magnussen S. *Perceptual filling-in from the edge of the blind spot*. *Vision Res* 2006;46:4252-7.
- Fiorani JM, Rosa MG, Gattass R, Rocha-Miranda CE. *Dynamic surrounds of receptive fields in primate striate cortex: a physiological basis for perceptual completion?* *Proc Natl Acad Sci U S A* 1992;89:8547-51.
- Komatsu H, Kinoshita M, Murakami I. *Neural responses in the retinotopic representation of the blind spot in the macaque V1 to stimuli for perceptual filling-in*. *J Neurosci* 2000;20:9310-19.
- Awatier H, Kerlin JR, Evans KK, Tong F. *Cortical representation of space around the blind spot*. *J Neurophysiol* 2005;94:3314-24.
- Troxler D. *Ueber das Verschwinden gegebener Gegenstände innerhalb unseres Gesichtskreises*. In: *Ophthalmische Bibliothek* 1804;1-119. Jena: F Frommann.
- Ramachandran V and Gregory R. *Perceptual filling-in of artificially induced scotomas in human vision*. *Nature* 1991;350:699-702.
- Troncoso XG, Macknik SL, Martinez-Conde S. *Microsaccades counteract perceptual filling-in*. *J Vis* 2008;8:15-19.
- De Weerd P, Desimone R, Ungerleider LG. *Perceptual filling-in: a parametric study*. *Vision Res* 1998;38:2721-34.
- Welchman AE, Harris JM. *Filling-in the details on perceptual fading*. *Vision Res* 2001;41:2107-17.
- De Weerd P, Gattass R, Desimone R, Ungerleider LG. *Responses of cells in monkey visual cortex during perceptual filling-in of an artificial scotoma*. *Nature* 1995;377:731-4.
- Weil RS, Kilner JM, Haynes JD, Rees G. *Neural correlates of perceptual filling-in of an artificial scotoma in humans*. *Proc Natl Acad Sci U S A* 2007;104:5211-16.
- Weil RS, Watkins S, Rees G. *Neural correlates of perceptual completion of an artificial scotoma in human visual cortex measured using functional MRI*. *Neuroimage* 2008;42:1519-28.
- De Weerd P, Smith E, Greenberg P. *Effects of Selective Attention on Perceptual Filling-in*. *J Cogn Neurosci* 2006;18:335-47.
- Rensink RA, Enns JT. *Early completion of occluded objects*. *Vision Res* 1998;38:2489-505.
- Nakayama K, Shimojo S, Silverman GH. *Stereoscopic depth: its relation to image segmentation, grouping, and the recognition of occluded objects*. *Perception* 1989;18:55-68.
- Johnson JS, Olshausen BA. *The recognition of partially visible natural objects in the presence and absence of their occluders*. *Vision Res* 2005;45:3262-76.
- Murray MM, Imber ML, Javitt DC, Foxe JJ. *Boundary completion is automatic and dissociable from shape discrimination*. *J Neurosci* 2006;26:12043-54.
- Hegde J, Fang F, Murray SO, Kersten D. *Preferential responses to occluded objects in the human visual cortex*. *J Vis* 2008;8:16.
- Zur D, Ullman S. *Filling-in of retinal scotomas*. *Vision Res* 2003;43:971-82.
- Gerrits HJ, Timmerman GJ. *The filling-in process in patients with retinal scotomata*. *Vision Res* 1969;9:439-42.
- Alvarenga DP, Couto MF, Pessoa VF. *Filling in at partially deafferented visual cortex*. *Br J Ophthalmol* 2008;92:1257-60.
- Crossland MD, Bex PJ. *Spatial alignment over retinal scotomas*. *Invest Ophthalmol Vis Sci* 2009;50:1464-9.
- Gilbert CD, Wiesel TN. *Receptive field dynamics in adult primary visual cortex*. *Nature* 1992;356:150-2.
- Chino YM, Kaas JH, Smith EL, III, Langston AL, Cheng H. *Rapid reorganization of cortical maps in adult cats following restricted deafferentation in retina*. *Vision Res* 1992;32:789-96.
- Matsuura K, Zhang B, Mori T, Smith EL, III, Kaas JH, Chino Y. *Topographic map reorganization in cat area 17 after early monocular retinal lesions*. *Vis Neurosci* 2002;19:85-96.
- Zepeda A, Vaca L, Arias C, Sengpiel F. *Reorganization of visual cortical maps after focal ischemic lesions*. *J Cereb Blood Flow Metab* 2003;23:811-20.
- Baker CI, Peli E, Knouf N, Kanwisher NG. *Reorganization of visual processing in macular degeneration*. *J Neurosci* 2005;25:614-18.
- Dilks DD, Serences JT, Rosenau BJ, Yantis S, McCloskey M. *Human adult cortical reorganization and consequent visual distortion*. *J Neurosci* 2007;27:9585-94.
- Baker CI, Dilks DD, Peli E, Kanwisher N. *Reorganization of visual processing in macular degeneration: replication and clues about the role of foveal loss*. *Vision Res* 2008;48:1910-19.
- Masuda Y, Dumoulin SO, Nakadomari S, Wandell BA. *V1 projection zone signals in human macular degeneration depend on task, not stimulus*. *Cereb Cortex* 2008;18:2483-93.
- Das A, Gilbert CD. *Long-range horizontal connections and their role in cortical reorganization revealed by optical recording of cat primary visual cortex*. *Nature* 1995;375:780-4.
- Angelucci A, Levitt JB, Walton EJ, Hupe JM, Bullier J, Lund JS. *Circuits for local and global signal integration in primary visual cortex*. *J Neurosci* 2002;22:8633-46.
- Darian-Smith C, Gilbert CD. *Axonal sprouting accompanies functional reorganization in adult cat striate cortex*. *Nature* 1994;368:737-40.
- Weil RS, Plant GT, James-Galton M, Rees G. *Neural correlates of hemianopic completion across the vertical meridian*. *Neuropsychologia* 2009;47:457-64.